Peptide record

TPDB91257

Lasioglossin - III LL-III LL-III/37 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard

15 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91257

Peptide_Name

Lasioglossin - III LL-III LL-III/37

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb AVPpred-BWR APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

VNWKKILGKIIKVVK-NH2

FASTA

>TPDB91257|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Hemolysis;Toxicity|length=15
VNWKKILGKIIKVVK-NH2

Formula C86H152N22O17

Absent Amino Acids ARDCEQHMFPSTY

Common Amino Acids K

Mass 1766.29

PI 11.12

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +5

Boman Index 2.25

Hydrophobicity 0.373

Aliphatic Index 162.00

Half Life

Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 311.39

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 1 K: 5 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 3

Length

Formula

C86H152N22O17

Mass

1766.29

11.12

Net Charge

Boman Index

2.25

Hydrophobicity

0.373

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial and Antifungal Antimicrobial

Origin

Lasioglossin III and its analogs Lasioglossum laticeps

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 4±1 µM

Detail Source Activity Anticancer

Activity Measurement 4

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 5±1 µM

Detail Source Activity Anticancer

Activity Measurement 5

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 18±4 µM

Detail Source Activity Anticancer

Activity Measurement 18

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 13 µM

Detail Source Activity Anticancer

Activity Measurement 13 µM

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 5±3 µM

Detail Source Activity Anticancer

Activity Measurement 5

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 4±1 µM

Detail Source Activity Anticancer

Activity Measurement 4

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 26.36 µM

Detail Source Activity Anticancer

Activity Measurement 26.36 µM

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2023

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 7.75 µM

Detail Source Activity Anticancer

Activity Measurement 7.75 µM

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay Not Available

Testing Time Not Available

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2023